ERBB2 and neoplasm: Figure 2 illustrates one such case, with globally negative HER2 but a minor component (<10%) with HER2 expression (3+) and PD-L1 CPS ≥ 5, revealing histological regions of the tumor component depicting mutually exclusive expressions of HER2 and PD-L1 biomarkers.